Highlights
- Bioventix Plc develops and supplies sheep monoclonal antibodies used in clinical diagnostic tests.
- A Dividend of 80 pence per share went ex-dividend on 6 November 2025 and was paid on 21 November 2025.
- A dividend of 70 pence per share went ex-dividend on 9 April 2026 and was paid on 24 April 2026.
- Its financial year ends on 30 June, and interim results were issued on 30 March 2026.
Bioventix Plc (LSE:BVXP) is an AIM-quoted Business that develops antibodies for diagnostic tests. It pays dividends in two instalments in the autumn and spring, and this article sets out the latest payments and the business behind them.
Business overview
Bioventix Plc generates monoclonal antibodies from sheep and licenses them to diagnostics manufacturers, which use them in blood tests. The company earns royalties on the sales of tests that contain its antibodies, so its income follows the Volume of testing by its customers rather than the cost of manufacturing. Its financial year ends on 30 June, and its shares are quoted in pence on AIM.
Royalty income carries high margins because the company does not manufacture or sell the finished tests, and it has a policy of distributing a high proportion of its earnings. Results are reported twice a year, with the interim announcement in the spring and the final results in the autumn, and each sets out revenue, profit and the dividend.
Dividend record
Bioventix Plc paid a dividend of 80 pence per share with an ex-dividend date of 6 November 2025 and payment on 21 November 2025. A second dividend of 70 pence per share followed, with an ex-dividend date of 9 April 2026 and payment on 24 April 2026. The two payments are 150 pence per share across the autumn and spring instalments.
How the dividend timetable works
Reading a dividend record is easier when the dates are kept apart. The declaration date is when the amount is announced, the ex-dividend date fixes who qualifies, the Record Date is the register check and the payment date is the cash settlement. Bioventix publishes these in its announcements, and the entries for LSE:BVXP above can be matched to them one by one. Final dividends usually need Shareholder approval at the Annual General Meeting before they are paid.
Dividend cover and sustainability
Sustainability is judged by looking at how much of Earnings and Cash Flow is paid out. Bioventix presents earnings per share, Dividend per share and its Capital allocation approach in its annual and half-year reports, which lets readers compare the amounts listed above with profit. A dividend that is comfortably covered gives the board room to keep paying through quieter periods, while a tightly covered one leaves less room for change.
The company has a policy of distributing a high proportion of earnings, as described in its annual report. Because the dividend is large in pence terms, readers should compare it with Earnings Per Share in the same report.
Recent company announcements
Interim results were issued on 30 March 2026 and covered the six months to 31 December 2025. The interim results announcement is where the spring dividend is declared.
Factors to watch
Several factors can influence future payments from Bioventix: trading conditions in its markets, cash generation, Balance Sheet commitments and the board's view of capital needs. The company explains its outlook in its results and trading updates. Each future dividend is a decision for the board at the time it is declared, and the announcements for LSE:BVXP are the place to confirm it.
Royalty income depends on the volume of tests sold by its customers and on the performance of the antibodies it has licensed. The company describes its outlook in its trading updates and results.
One practical way to follow a dividend payer is to keep a simple calendar of its reporting and ex-dividend dates. For Bioventix that calendar is set by its interim and final announcements, and the dates listed above give a template for the year. The Investor relations pages of the company also carry its financial calendar.
A single year of dividends is only one view of how a company treats its shareholders. Comparing several years of dividend per share with earnings per share, cash generation and the balance sheet gives a fuller picture. Bioventix publishes the information needed for that comparison in its annual report, and the company's investor relations pages are the place to find it.
The figures in this article are taken from the company's own dividend announcements and reports. Where a payment is quoted in a currency other than sterling, the amount is stated in that currency, as the company declares it. Shareholders can compare any figure here with the original announcement to confirm the amount, the ex-dividend date and the payment date.
Dividend information is most useful when read alongside the full results. The amount per share, the number of shares in issue and the profit for the period together show how much cash is needed for each payment. Bioventix publishes these figures in its reports, and shareholders can use them to follow how the distribution develops from one reporting period to the next.
It can help to remember that a dividend is a decision, not an entitlement. The board of Bioventix reviews trading, cash and its plans before each declaration, and the amount can rise, stay level or change as circumstances move. The most reliable reference is always the latest announcement from the company itself.






Please wait processing your request...